CAR immune cells: design principles, resistance and the next generation
L Labanieh, CL Mackall - Nature, 2023 - nature.com
The remarkable clinical activity of chimeric antigen receptor (CAR) therapies in B cell and
plasma cell malignancies has validated the use of this therapeutic class for liquid cancers …
plasma cell malignancies has validated the use of this therapeutic class for liquid cancers …
[HTML][HTML] Emerging therapies for glioblastoma: current state and future directions
L Rong, N Li, Z Zhang - Journal of Experimental & Clinical Cancer …, 2022 - Springer
Glioblastoma (GBM) is the most common high-grade primary malignant brain tumor with an
extremely poor prognosis. Given the poor survival with currently approved treatments for …
extremely poor prognosis. Given the poor survival with currently approved treatments for …
Engineered cellular immunotherapies in cancer and beyond
AV Finck, T Blanchard, CP Roselle, G Golinelli… - Nature medicine, 2022 - nature.com
This year marks the tenth anniversary of cell therapy with chimeric antigen receptor (CAR)-
modified T cells for refractory leukemia. The widespread commercial approval of genetically …
modified T cells for refractory leukemia. The widespread commercial approval of genetically …
Glioblastoma multiforme (GBM): An overview of current therapies and mechanisms of resistance
Glioblastoma multiforme (GBM) is a WHO grade IV glioma and the most common malignant,
primary brain tumor with a 5-year survival of 7.2%. Its highly infiltrative nature, genetic …
primary brain tumor with a 5-year survival of 7.2%. Its highly infiltrative nature, genetic …
Recent advances and discoveries in the mechanisms and functions of CAR T cells
This Review discusses the major advances and changes made over the past 3 years to our
understanding of chimeric antigen receptor (CAR) T cell efficacy and safety. Recently, the …
understanding of chimeric antigen receptor (CAR) T cell efficacy and safety. Recently, the …
Navigating CAR-T cells through the solid-tumour microenvironment
AJ Hou, LC Chen, YY Chen - Nature reviews Drug discovery, 2021 - nature.com
The adoptive transfer of T cells that are engineered to express chimeric antigen receptors
(CARs) has shown remarkable success in treating B cell malignancies but only limited …
(CARs) has shown remarkable success in treating B cell malignancies but only limited …
Intraventricular CARv3-TEAM-E T cells in recurrent glioblastoma
BD Choi, ER Gerstner, MJ Frigault… - … England Journal of …, 2024 - Mass Medical Soc
In this first-in-human, investigator-initiated, open-label study, three participants with recurrent
glioblastoma were treated with CARv3-TEAM-E T cells, which are chimeric antigen receptor …
glioblastoma were treated with CARv3-TEAM-E T cells, which are chimeric antigen receptor …
[HTML][HTML] Cytotoxic CD8+ T cells in cancer and cancer immunotherapy
H Raskov, A Orhan, JP Christensen… - British journal of cancer, 2021 - nature.com
The functions of, and interactions between, the innate and adaptive immune systems are
vital for anticancer immunity. Cytotoxic T cells expressing cell-surface CD8 are the most …
vital for anticancer immunity. Cytotoxic T cells expressing cell-surface CD8 are the most …
SynNotch-CAR T cells overcome challenges of specificity, heterogeneity, and persistence in treating glioblastoma
JH Choe, PB Watchmaker, MS Simic… - Science translational …, 2021 - science.org
Treatment of solid cancers with chimeric antigen receptor (CAR) T cells is plagued by the
lack of ideal target antigens that are both absolutely tumor specific and homogeneously …
lack of ideal target antigens that are both absolutely tumor specific and homogeneously …
[HTML][HTML] CAR-T: what is next?
YJ Chen, B Abila, Y Mostafa Kamel - Cancers, 2023 - mdpi.com
Simple Summary In 2017, two chimeric antigen receptor-T (CAR-T) therapies were
approved by the FDA for advanced/resistant lymphoma and acute lymphoblastic leukemia …
approved by the FDA for advanced/resistant lymphoma and acute lymphoblastic leukemia …